Russell Cohen to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Russell Cohen has written about Randomized Controlled Trials as Topic.
Connection Strength
0.078
-
Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review. Adv Ther. 2025 Mar; 42(3):1360-1392.
Score: 0.042
-
The mesalamine wars heat up-enter balsalazide. Gastroenterology. 2003 Feb; 124(2):574-5.
Score: 0.036